Acute Ischemic Stroke Flashcards
Common stroke sx
sudden onset unilateral focal neuro deficit
* dysphasia,dysarthria
* hemianopia
* weakness
* ataxia
* sensory loss
* neglect
Stroke severity
Assess using NIHSS
1-4 = minor stroke
21-42 = severe stroke
Small stroke: no visible difference MRI
Large stroke: large vessel occlusion
Acute stroke diagnosis
Confirm NIHSS (+) stroke
Confirm sx dt ischemia +r/o other neuro deficit
Consider stroke mimics
Imaging!!!
1. non contrast CT head r/o hemorrhage
2. MRI sensitive for detecting early ischemic changes
Ischemic vs hemorrhagic stroke on imaging
Ischemic: not seen until 12-24 hr post event
Hemorrhagic: shows up 1-2 hrs post event on CT
Ischemic Stroke Mimics - neurological
- seizure/post ictal
- complicated migraine
- otherintracrainal process (infx, abcess, hemorrhage, MS)
- HTN encephalopathy
- Vertigo
- Crania/peripheral neuropathies
- Bells palsy
- transient global amnesia
Ischemic Stroke Mimics - Metabolic
Hypo/hyperglycemia
Low sodium
hepatic encephalopathy
Drug overdose
Ischemic Stroke Mimics - Psychiatric
Conversion disorder
malingering
Post stroke regimen
post TPA
- Neuro/BP monitor x 24 hrs (neuro decline usually occurs first 24-48hr post)
- Dysphagia/aspiriation risk
- HIGH INTENSITY STATIN
- AntiPLT:
* Everyone: spirin 81 mg
* Low NIH or stent: 21 day DAPT - DVT prophy once >24 hr post TPA
- Anticoag: if cardioembolic stroke or hx afib
* large = 7-14 days
* small = 3-5 days
Stroke Prevalence
ischemic
4th leading cause death
cerebral ischemia = 87% strokes/yr that occur in US
Post-stroke deficits
complications
50% hemiparesis
46% cognitive decline
35% depression
30% inability to ambulate w/o assistance
23% PTSD
Risk factors of Ischemic Stroke
Hypertension
Cigarette smoking
Diabetes
Dyslipidema
Arrythmia conditions
Post menopausal hormone therapy (estrogens)
Oral contraceptives
Physical inactivity
Obesity
Harder to modify:
- asymptomatic carotid stenosis
- sickle cell disease
CH A2 D S2-VASc
Congestive HF
HTN
Age
Diabetes
Stroke/TIA hx 2pt
Vascular disease
Female
age 75+ = 2pts
Ischemic stroke patho
ischemia dt excess extracellular amino acids, free radicals, inflammation
Atherosclerotic plaque rupture
Cardiogenic afib - embolism = 20% strokes
Acute stroke management
within 4.5 hrs sx onset
Fibrinolysis of no C/I
If large vessel stroke = thrombectomy
if small vessel occlusion = only heparin infusion
if >4.5 hrs, no TPA
IV fibrinolytic contraindications
<18
within 3 mon:
* ischemic stroke
* intracranial/spinal surgery
GI malignancy/BIG within 21 days
LMWH within 24 hrs
Infective endocarditis
intra-axial intracranial neoplasm
IV fibrinolytics OK use
once you correct the problems
Seizure at onset
hypo/hyperglycemia
arterial puncture at non-compressible site in last 7 days
recent major trauma if not involving head in last 14 days
recent major surgery within 14 days
IV fibrinolytic choices
- alteplase
- tenecteplase
alteplase dose
0.9 mg/kg
Max dose 90mg
Bolus: 10% IV bolus over 1 min
Infusion: 90% total dose over 60 min
alteplase half life
5 minutes
80% cleared from plasma within 10 minutes
super short acting
tenecteplase dose
0.25 mg/kg
Max dose 25mg
IV push dt longer half life
tenecteplase half life
20-24 minutes
terminal: 99-120 min
TPA specficity
tenecteplase 15x fold increase in fibrin specificity vs alteplase
BP for TPA bolus
<185/110
BPA for TPA infusion
<180/105
more fluid, lower bp goal than bolus
BP if not qualify TPA
permissive HTN
no treat unless >220/110 to maintain brain perfusion
Hypotension vs stroke
low bp can worsen ischemia
HTN vs Stroke
> 220/120 detrimental = risk of hemorrhagic conversion
BP control first line
IV labetalol bolus
IV nicardipine if HR < 55
BP control 2nd line
hydralazine
enalaprilat
clevidipine
Alteplase usage data
increased sx ICH (hemorrage risk)
Alteplase vs timing
alteplase use ≥4.5 hrs
Wakeup/EXTEND trials
extended time frame TPA = improved functional outcomes as long as use MRI/CT guided scan for pt TX inclusion
Tenecteplase usage data
EXTEND-IA trial: ≤4.5 hrs w/ large vessel occlusion
as good as alteplase if not better reperfusion/functional outcomes when used with thrombectomy
TPA complications
Symptomatic ICH
1. DC TPA
2. Cryoprecipitate 10 units over 10-30 min (supplements fibrinogen by 30-60 mg/dL)
3. Anti-TPA: tranexamic acid 100mg IV or e-aminocaproic acid 4-5g IV
Angioedema 5% patient, ACEI risk factor
1. maintain airway - intubate before too late
2. Hold ACEi
3. IV steroid: MnPn 80-100mg IV
4. Benadryl 50mg IV
5. Ranitidine 50mg IV or famotidine 20mg IV
6. EPI 0.3mL
7. watch for swelling to come down
anti-TPA: displace plasminogen from fibrin (inhibit fibrinolysis)
thrombectomy
Endovascular intervention
for large vessel occlusions +/- use of IA thrombolytics
secondary stroke prevention
lifestyle/nutrition
smoking cessation
limit alcohol consumption
counsel SUD
HTN
Dyslipidemia
Diabetes
MR CLEAN trial
thrombectomy
IA alteplase +/- thrombectomy
= significant improvement in functional outcome
no difference in mortality or ICH